News
SYRS
1.930
-1.03%
-0.020
Weekly Report: what happened at SYRS last week (0930-1004)?
Weekly Report · 4d ago
Weekly Report: what happened at SYRS last week (0923-0927)?
Weekly Report · 09/30 09:01
Weekly Report: what happened at SYRS last week (0916-0920)?
Weekly Report · 09/23 09:01
Weekly Report: what happened at SYRS last week (0909-0913)?
Weekly Report · 09/16 09:01
Syros Pharmaceuticals Chief Financial Officer Acquires 407% More Stock
Simply Wall St · 09/14 13:20
Weekly Report: what happened at SYRS last week (0902-0906)?
Weekly Report · 09/09 09:01
Syros Pharmaceuticals Reports SELECT-AML-1 Trial Outcomes
TipRanks · 09/05 12:10
Weekly Report: what happened at SYRS last week (0826-0830)?
Weekly Report · 09/02 09:01
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Barchart · 08/27 06:00
Weekly Report: what happened at SYRS last week (0819-0823)?
Weekly Report · 08/26 09:01
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
Barchart · 08/20 20:11
Weekly Report: what happened at SYRS last week (0812-0816)?
Weekly Report · 08/19 09:01
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
NASDAQ · 08/14 14:19
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NASDAQ · 08/14 13:35
BUZZ-U.S. STOCKS ON THE MOVE-Paysafe, HUYA, Oklo
Reuters · 08/13 18:29
S&P 500 Gains 1%; Home Depot Earnings Top Views
Benzinga · 08/13 16:15
BUZZ-U.S. STOCKS ON THE MOVE-Penumbra, Talen Energy, Paysafe
Reuters · 08/13 16:02
Syros Pharmaceuticals Price Target Cut to $5.00/Share From $13.00 by Piper Sandler
Dow Jones · 08/13 15:43
Piper Sandler Reiterates Overweight on Syros Pharmaceuticals, Lowers Price Target to $5
Benzinga · 08/13 15:32
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Benzinga · 08/13 13:54
More
Webull provides a variety of real-time SYRS stock news. You can receive the latest news about Syros Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).